|Articles|September 1, 2003

Adjuvant androgen ablation plus RT reduces PCa failure

Chicago-Adjuvant androgen ablation following radiation therapysignificantly reduces the risk of local and distant failure and significantlyimproves overall survival in patients with unfavorable-prognosis prostatecancer, according to 10-year results from a large cooperative group trial.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe

Related Content

Published data show rPFS benefit with lutetium Lu 177 vipivotide tetraxetan in mHSPC

ByHannah Clarke

August 8th 2026

Elizabeth Nally, MBBS, on decision regret and toxicity perception with adjuvant pembrolizumab

ByElizabeth Nally, MBBS

August 7th 2026

The UroOnc Minute: Navigating BCG Maintenance Therapy in NMIBC, With Mark D. Tyson, II, MD, MPH

ByAdam B. Weiner, MD,Mark D. Tyson, MD, MPH

August 7th 2026

Optimizing care for men with overactive bladder, with Keith Xavier, MD

ByKeith Xavier, MD, URPS

August 6th 2026

Neil Baum, MD, and Abraham Morgentaler, MD, discuss the history of testosterone and prostate cancer

ByNeil H. Baum, MD,Abraham Morgentaler, MD

August 6th 2026

Latest CME

Video

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Video

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Adjuvant androgen ablation plus RT reduces PCa failure

Related Content

Published data show rPFS benefit with lutetium Lu 177 vipivotide tetraxetan in mHSPC

Elizabeth Nally, MBBS, on decision regret and toxicity perception with adjuvant pembrolizumab

The UroOnc Minute: Navigating BCG Maintenance Therapy in NMIBC, With Mark D. Tyson, II, MD, MPH

Optimizing care for men with overactive bladder, with Keith Xavier, MD

Neil Baum, MD, and Abraham Morgentaler, MD, discuss the history of testosterone and prostate cancer

Latest CME

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Trending on Urology Times

Elizabeth Nally, MBBS, on decision regret and toxicity perception with adjuvant pembrolizumab

Neil Baum, MD, and Abraham Morgentaler, MD, discuss the history of testosterone and prostate cancer

Optimizing care for men with overactive bladder, with Keith Xavier, MD

The UroOnc Minute: Navigating BCG Maintenance Therapy in NMIBC, With Mark D. Tyson, II, MD, MPH

FDA clears Revi Extend implant for urgency urinary incontinence